<DOC>
	<DOCNO>NCT02166021</DOCNO>
	<brief_summary>The purpose study evaluate optimal dosage way administration autologous mesenchymal bone marrow stem cell ( MSC ) either maximal proximity lesion CNS intrathecal injection CSF .</brief_summary>
	<brief_title>Optimal Administration Mode Autologous Mesenchymal Bone Marrow Stem Cells Active Progressive Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>1 . Consenting patient fulfil Poser 's clinical criterion definite MS 2 . Age : 2565 , male females 3 . Duration disease : &gt; 3 year 4 . Progressive form MS ( RPMS , SPMS ) 5 . EDSS score 3.0 6.5 6 . Failure currently available , register first second line immunomodulatory treatment 7 . Evidence new activity MS 3 month injection MSC . 1 . Patients treat cytotoxic medication last 3 month prior inclusion . 2 . Patients suffer significant cardiac , renal hepatic failure disease may risk patient interfere ability interpret result 3 . Patients active infection 4 . Patients severe cognitive decline inability understand sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Multiple Sclerosis ( MS )</keyword>
	<keyword>Stem Cells</keyword>
</DOC>